In his new position, Mr. Richard will be responsible for developing PDI’s molecular diagnostics growth strategy, according to a news release.
“Molecular Diagnostics is a fast-growing market that represents a significant opportunity for PDI,” said Nancy Lurker, CEO of PDI, in the release. “Greg’s dynamic experience in developing strategy, driving revenue growth and his relationships with payers in molecular diagnostics is exactly what we sought to help PDI execute our long term strategic vision.”
